Daiichi Sankyo Company, Limited DSNKY
Set alert
As of Nov 3, 12:53 PM ET
- YTD
- -14.55%
- 1 year
- -23.42%
- Open
- 18.25
- Prev close
- 18.19
- Mkt cap
- 33.07B
- Vol
- 3.84K
- Avg vol
- 114.79K
- EPS
- 0.97
- P/E
- 18.71
More statistics
- Low
- 18.15
- High
- 18.25
- Earnings
- Oct 30, 2026
News
4 days ago seekingalpha.com
Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript
4 days ago businesswire.com
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026. “Strong revenue growth continues in the second…
5 days ago businesswire.com
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union
MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination…
-
1 week ago benzinga.com
Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1First EU…
1 week ago businesswire.com
Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO.
2 weeks ago zacks.com
COLL vs. DSNKY: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
4 weeks ago seekingalpha.com
Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript
1 month ago benzinga.com
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.
1 month ago reuters.com
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration with Summit Therapeutics to test their cancer drug, Datroway, in combination with Summit's ivonescimab across multiple…
-
1 month ago benzinga.com
Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study
Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer
1 month ago reuters.com
Merck, Daiichi Sankyo withdraw US application for lung cancer drug
Merck and Daiichi Sankyo have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the drugmakers said on Friday.
1 month ago reuters.com
Malaysia's IHH's unit appeals Tokyo court's rejection of Daiichi Sankyo damages claim
Malaysia's IHH Healthcare said on Thursday its subsidiary has appealed a Tokyo court's dismissal of its damages claim against Daiichi Sankyo over the unit's acquisition of a stake in India's Fortis…
1 month ago defenseworld.net
Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up on Analyst Upgrade
Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) gapped up prior to trading on Tuesday after Zacks Research upgraded the stock from a strong sell rating to a hold rating.…
-
1 month ago benzinga.com
Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial
6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression…
2 months ago businesswire.com
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a…
2 months ago businesswire.com
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization.
2 months ago businesswire.com
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company's…
-
2 months ago benzinga.com
Daiichi Sankyo And AstraZeneca's Enhertu Shows Significant PFS Improvement As First-Line HER2 Mutant NSCLC Treatment In DESTINY-Lung04 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve progression-free survival over global standard of care in a phase 3 trial in this settingData to be…
3 months ago seekingalpha.com
Daiichi Sankyo Company, Limited (DSNKY) Q1 2027 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSNKY) Q1 2027 Earnings Call Transcript
3 months ago businesswire.com
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the…
3 months ago defenseworld.net
Daiichi Sankyo (OTCMKTS:DSNKY) & Shuttle Pharmaceuticals (NASDAQ:SHPH) Head to Head Contrast
Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) are both medical companies, but which is the better business? We will contrast the two…
4 months ago seekingalpha.com
Daiichi Sankyo: Not Exciting Enough For This Market, Apparently
Daiichi Sankyo maintains strong growth prospects, driven by its expanding antibody-drug conjugate (ADC) pipeline and disciplined oncology development. Trastuzumab deruxtecan remains a key growth…
5 months ago businesswire.com
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with…
5 months ago seekingalpha.com
Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript
5 months ago businesswire.com
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in…
-
9 months ago benzinga.com
Organon Signs Commercialization Agreement For Daiichi Sankyo's Nilemdo To Strengthen Cardiovascular Disease Portfolio In France And Nordic Countries
The agreement builds on Organon's cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This…
-
2 years ago benzinga.com
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
Japanese stocks are gaining favor among I-banks and sport attractive valuations; here are 3 stocks with low P/B that have outperformed and could generate shareholder wealth.
-
6 years ago benzinga.com
Earnings Scheduled For July 31, 2020
Companies Reporting Before The Bell • Chevron Inc. (NYSE:CVX) is expected to report quarterly loss at $0.92 per share on revenue of $22.10 billion. • Weyerhaeuser Inc. (NYSE:WY) is estimated to…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
Stocks That Hit 52-Week Highs On Thursday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Highs On Monday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday
-
7 years ago benzinga.com
Stocks That Managed to Breach 52-Week Highs Wednesday Morning
Stocks That Managed to Breach 52-Week Highs Wednesday Morning